The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis’s oncology capabilities.
Source link
About The Author
Novartis to Buy Myricx Bio for Up to $1.5 Billion
The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis’s oncology capabilities.
Source link